Stockscreener 앱 받기
1.55
1.90%
-0.03
시장 영업 전:
1.54
-0.01
-0.65%
전일 마감가:
$1.58
열려 있는:
$1.59
하루 거래량:
721.50K
Relative Volume:
0.48
시가총액:
$82.87M
수익:
-
순이익/손실:
$-59.69M
주가수익비율:
-1.1151
EPS:
-1.39
순현금흐름:
$-46.54M
1주 성능:
+4.03%
1개월 성능:
-16.67%
6개월 성능:
-21.72%
1년 성능:
+2.65%
1일 변동 폭
$1.52
$1.59
1주일 범위
$1.49
$1.64
52주 변동 폭
$0.6254
$2.75
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
명칭
Milestone Pharmaceuticals Inc
전화
(514) 336-0444
주소
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
MIST을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
1.55 | 134.24M | 0 | -59.69M | -46.54M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.83 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.63 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.79 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
595.19 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.51 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-05 | 재개 | H.C. Wainwright | Buy |
| 2024-08-22 | 개시 | Rodman & Renshaw | Buy |
| 2023-06-20 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-22 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-03-05 | 개시 | H.C. Wainwright | Buy |
| 2020-07-29 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-07-24 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-03-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-03-24 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-03-24 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2019-06-04 | 개시 | Oppenheimer | Outperform |
| 2019-06-03 | 개시 | Cowen | Outperform |
| 2019-06-03 | 개시 | Jefferies | Buy |
| 2019-06-03 | 개시 | Piper Jaffray | Overweight |
모두보기
Milestone Pharmaceuticals Inc 주식(MIST)의 최신 뉴스
Published on: 2025-07-29 04:32:28 - beatles.ru
How volatile is Milestone Pharmaceuticals Inc. stock compared to the marketGet exclusive market analysis for investors - jammulinksnews.com
Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics - Business Wire
What are analysts’ price targets for Milestone Pharmaceuticals Inc. in the next 12 monthsFree Stock Insights For Every Investor - jammulinksnews.com
How does Milestone Pharmaceuticals Inc. compare to its industry peersBuild wealth faster with high-performing stocks - jammulinksnews.com
Is it the right time to buy Milestone Pharmaceuticals Inc. stockFree Capital Allocation Plans - jammulinksnews.com
Is Milestone Pharmaceuticals Inc. stock overvalued or undervaluedSuperior returns - jammulinksnews.com
Should I hold or sell Milestone Pharmaceuticals Inc. stock in 2025Invest smarter with high-probability setups - jammulinksnews.com
What makes Milestone Pharmaceuticals Inc. stock price move sharplyMaximize profits with strategic stock selection - jammulinksnews.com
Is Milestone Pharmaceuticals Inc. stock a good hedge against inflationFree Access to Group - metal.it
Why Milestone Pharmaceuticals Inc. stock attracts strong analyst attentionFree Stock Investment Discussion Area - metal.it
Atrial Fibrillation (AF) Pipeline Market Research Report 2025 | Insights on 10+ Companies and 12+ Drugs in the Pipeline Landscape - GlobeNewswire Inc.
Is Milestone Pharmaceuticals Inc. a good long term investmentExtraordinary earning power - PrintWeekIndia
What drives Milestone Pharmaceuticals Inc. stock priceExceptional trading results - Autocar Professional
Milestone Pharmaceuticals Inc. Stock Analysis and ForecastFree Stock Movement Tracking - Autocar Professional
Is Milestone Pharmaceuticals Inc. stock a growth or value playFree Advanced Stock Screener Access - jammulinksnews.com
What analysts say about Milestone Pharmaceuticals Inc. stockConsistently superior profits - Autocar Professional
Milestone Pharmaceuticals Remains A Buying Opportunity Despite Recent Dilution (MIST) - Seeking Alpha
Piper Sandler Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Cuts Target Price to $4 - 富途牛牛
HC Wainwright Has Positive Estimate for MIST Q3 Earnings - Defense World
Milestone Pharmaceuticals plunges after pricing $52.5M offering - MSN
How Milestone Pharmaceuticals Inc. stock performs during market volatilityPrecision Entry Strategy - Newser
Retail investors who have a significant stake must be disappointed along with institutions after Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) market cap dropped by US$9.0m - simplywall.st
Milestone Pharmaceuticals Inc (MIST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.32%
1.06%
자본화:
|
볼륨(24시간):